Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early-stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology.